Recruiting

A Study to Evaluate Splenectomy on Debridement for Acute Necrotizing Pancreatitis With Pancreatic Sinistral Portal Hypertension

This study is a prospective, single-center, randomized controlled trial focusing on patients with acute necrotizing pancreatitis (ANP) complicated by pancreatic sinistral portal hypertension (PSPH). The study aims to study the impact of total splenectomy on the debridement efficacy, perioperative recovery, and prognosis of patients with ANP complicated by PSPH.

I'm interested View official listing

ClinicalTrials.gov IDNCT07080697

PhaseNA

Enrollment66

SponsorZhejiang University

Age18 Years – 75 Years

SexALL

I'm interested View official listing

Conditions studied

Acute Necrotizing Pancreatitis, Portal Hypertension

About this study

Interventions

Procedure: Splenectomy — Open Debridement combined with distal pancreatectomy and total splenectomy
Procedure: Control — Open Debridement alone

Primary outcomes

Length of hospital stay after debridement (From enrollment of the first subject to completion of follow-up of the last subject (up to 5 years))
Degree of pancreatic sinistral portal hypertension (From enrollment of the first subject to completion of follow-up of the last subject (up to 5 years))

Eligibility information

Inclusion Criteria: 1. Age between 18 and 75 years. 2. Acute necrotic pancreatitis complicated by pancreatic sinistral portal hypertension. 3. Patients undergoing open debridement for infected pancreatic necrosis Exclusion Criteria: 1. Patients with pre-existing heart, lung, liver, kidney, or other organ failure prior to acute pancreatitis (AP). 2. Patients with pre-existing conditions such as cirrhosis that may lead to portal hypertension prior to AP. 3. Patients with pre-existing hematological diseases prior to AP. 4. Patients undergoing laparoscopic or nephroscopic debridement.

Study locations

First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003 China

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-04.